FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the release of pharma rejection letters, issuing 14 Complete Response Letters (CRLs) following a three-month disclosure freeze.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has released 14 drug rejection letters, known as Complete Response Letters (CRLs), ending a three-month pause in disclosure. This resumption comes days after the agency confirmed the pause had been in place.
Coverage from Endpoints News, Fierce Biotech, and BioSpace emphasizes the volume of the new releases. Meanwhile, finance.biggo.com reports warnings from Sue Sutter and Derrick Gingery that the CRL disclosure freeze and a crackdown on direct-to-consumer (DTC) advertising may be headed for court.
Future developments involve the potential for legal challenges regarding the disclosure freeze and DTC ad regulations, as well as a shift toward protocol-centric recruitment models and medical affairs integration in development, according to Applied Clinical Trials Online.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 56m ago.
Quick answers
How many rejection letters did the FDA release?
The FDA released 14 new Complete Response Letters (CRLs).
How long was the pause on releasing these letters?
The disclosure freeze lasted for three months.
What other regulatory actions are mentioned as potentially facing court action?
Sue Sutter and Derrick Gingery warned that both the CRL disclosure freeze and a crackdown on direct-to-consumer (DTC) advertising could be headed for court.
Coverage (5)
- ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development Applied Clinical Trials Online · 9h ago
- FDA's CRL Disclosure Freeze and DTC Ad Crackdown Likely Headed for Court, Sue Sutter and Derrick Gingery Warn finance.biggo.com · 9h ago
- FDA posts new rejection letters days after confirming pause BioSpace · 9h ago
- FDA returns to releasing pharma rejection letters with 14 new CRLs Endpoints News · 9h ago
- FDA releases 14 drug rejection letters after 3-month pause Fierce Biotech · 9h ago broke it first
People, places & organizations
Topics
Related trends
Popular dog food recalled nationwide may contain sharp metal fragments, FDA says
A popular dog food brand is facing a nationwide recall after the FDA warned of potential sharp metal fragment contamination.
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes the first cancer drug to receive FDA approval for delivery via an on-body injector.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
FDA recalls eye drops over possible 'foreign substance'
The FDA has issued a nationwide recall of 2.5 million bottles of steroid eye drops due to contamination concerns.
Arsenic, lead and other metals in tampons aren’t harmful, FDA report concludes
9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
FDA approves Vera Therapeutics kidney disease treatment
The FDA has approved Vera Therapeutics' drug Trutakna to treat primary IgA nephropathy, sparking a new market competition for kidney disease treatments.